Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy - Contacts and Locations - ClinicalTrials.gov

ClinicalTrials.gov

Home

Search


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

This study is currently recruiting participants.

Study NCT00159250. Last updated on May 8, 2008. Information provided by Imperial College London

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159250

Contacts


Contact: Francesco Muntoni, FRCPCH	+442079052111	f.muntoni@imperial.ac.uk

Contact: Kinali Maria, MRCPCH	+ 44 2079052111	m.kinali@imperial.ac.uk

Locations


United Kingdom
	Dubowitz Neuromuscular Centre, Hammersmith Hospital and Clinical Trails Unit, St Mary's Hospital			Recruiting
	London, United Kingdom, W12 0HS
	Contact: Francesco Muntoni, FRCPCH +44 20 7905 2111 f.muntoni@imperial.ac.uk
	Contact: Maria Kinali, MRCPCH +44 20 7905 2111
	Principal Investigator: Francesco Muntoni, FRCPCH
	Sub-Investigator: Mary Rutherford, FRCR
	Sub-Investigator: Maria Kinali, MRCPCH
	Sub-Investigator: Virginia Arechavala, PhD
	Sub-Investigator: Caroline Sewry, PhD
	Sub-Investigator: Lucy Feng, PhD

Sponsors and Collaborators

Imperial College London

Department of Health

Investigators


Principal Investigator:	Francesco Muntoni, FRCPCH	Dubowitz neuromuscular Centre, Imperial College, London

Study Director:	Kate Bushby, MRCP	Institute of Human Genetics, University of Newcastle upon Tyne

Study Director:	Volker Straub, FRCPCH	Institute of Human Genetics, University of Newcastle upon Tyne